4.7 Article

Impulsivity and functional impairment in bipolar disorder

Journal

JOURNAL OF AFFECTIVE DISORDERS
Volume 136, Issue 3, Pages 491-497

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jad.2011.10.044

Keywords

Impulsivity; Functional impairment; Bipolar Disorder

Funding

  1. Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III
  2. Spanish Ministry of Education, CIBERSAM, IDIBAPS
  3. Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya [2009 SGR 827]
  4. Janssen-Cilag
  5. Pfizer
  6. Almirall
  7. Astra-Zeneca
  8. Bristol-Myers-Squibb
  9. Eli Lilly
  10. Generalitat de Catalunya
  11. Gedeon Richter
  12. Glaxo-Smith-Kline
  13. Johnson Johnson
  14. Novartis
  15. Sanofi-Aventis
  16. Servier
  17. Seventh European Framework Programme
  18. Spanish Ministry of Science and Innovation
  19. Instituto Carlos III [PI080247]
  20. Centro de Investigacion en Red de Salud Mental
  21. CIBERSAM
  22. Bipolar Disorders Group [2009 SGR 1022]
  23. Spanish Ministry of Education through a Juan de la Cierva [JCI-2009-04329]

Ask authors/readers for more resources

Background: Impulsivity is substantially higher in bipolar patients (BP) and may be associated with a more severe course of illness, but no studies have so far examined the relationship between impulsivity and functional outcome in BP. Our goal was to investigate the functional impact of trait-impulsivity in BP. Methods: 138 euthymic BP were recruited. All patients were assessed using an interview based on the Structured Clinical Interview for DSM Disorders (SCID). The Functioning Assessment Short Test (FAST) and the Barratt Impulsiveness Scale (BIS-11) were used to assess functional outcome and impulsivity, respectively. Seven multiple linear regressions, with each individual FAST subscale scores and overall FAST score as dependant variables, were conducted in order to evaluate the predictive role of trait-impulsivity on functional outcome. Results: After a multiple linear regression model, with the FAST total score as dependent variable, we found that depressive symptoms (beta=1.580; p<0.001), number of hospitalizations (beta=0.837; p=0.019) and impulsivity (beta=0.319; p=0.004) were independently associated with overall functional impairment (F=6.854, df=9, p<0.001, adjusted R-2=0.311). Limitations: The cross-sectional design of the study. Conclusions: Our results indicate that impulsivity, as well as depressive symptoms and the number of hospitalizations, is associated with overall functional impairment in BP. The assessment and treatment of impulsivity may be useful in improving functional outcome in BP. (C) 2011 Elsevier B.V. All rights reserved,

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available